Recombinant angiostatin prevents retinal neovascularization in a murine proliferative retinopathy model

P. I. Meneses, K. A. Hajjar, K. I. Berns, Robert Duvoisin

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Retinal neovascularization is central to the pathogenesis of proliferative diabetic retinopathy, the leading cause of blindness among the middle-aged population. Angiostatin, a proteolytic fragment of plasminogen is one of the most promising inhibitors of angiogenesis currently in clinical trials. Here we show that recombinant angiostatin can inhibit retinal neo-vascularization in a mouse model of proliferative retinopathy. Because proliferative diabetic retinopathy is a recurrent disease, effective therapy will need to be sustained. Recombinant adeno-associated viruses permit long-term expression of transfected genes; however, they can only accommodate a small insert sequence. Thus, we engineered and tested a shortened recombinant angiostatin derivative containing a signal sequence to permit secretion. Recombinant protein was purified from the medium of transfected HEK293 cells and injected subcutaneously into treated animals. The retinal vasculature was analyzed in retinal flat mounts and using immunohistochemically stained sections. Both methods demonstrate that this short, secreted form of angiostatin is effective in reducing the development of blood vessels in a nontumor environment and has therapeutic potential for neovascular retinopathies such as diabetic retinopathy retinopathy of prematurity, retinal vein occlusion and, possibly, age-related macular degeneration.

Original languageEnglish (US)
Pages (from-to)646-648
Number of pages3
JournalGene Therapy
Volume8
Issue number8
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Angiostatins
Retinal Neovascularization
Diabetic Retinopathy
Retinal Vein Occlusion
Dependovirus
Retinopathy of Prematurity
Angiogenesis Inhibitors
HEK293 Cells
Plasminogen
Macular Degeneration
Blindness
Protein Sorting Signals
Recombinant Proteins
Blood Vessels
Clinical Trials
Gene Expression
Therapeutics
Population

Keywords

  • Angiostatin
  • Neovascularization
  • Proliferative retinopathy

ASJC Scopus subject areas

  • Genetics

Cite this

Recombinant angiostatin prevents retinal neovascularization in a murine proliferative retinopathy model. / Meneses, P. I.; Hajjar, K. A.; Berns, K. I.; Duvoisin, Robert.

In: Gene Therapy, Vol. 8, No. 8, 2001, p. 646-648.

Research output: Contribution to journalArticle

Meneses, P. I. ; Hajjar, K. A. ; Berns, K. I. ; Duvoisin, Robert. / Recombinant angiostatin prevents retinal neovascularization in a murine proliferative retinopathy model. In: Gene Therapy. 2001 ; Vol. 8, No. 8. pp. 646-648.
@article{b082631ef5d342e68accbce24303d737,
title = "Recombinant angiostatin prevents retinal neovascularization in a murine proliferative retinopathy model",
abstract = "Retinal neovascularization is central to the pathogenesis of proliferative diabetic retinopathy, the leading cause of blindness among the middle-aged population. Angiostatin, a proteolytic fragment of plasminogen is one of the most promising inhibitors of angiogenesis currently in clinical trials. Here we show that recombinant angiostatin can inhibit retinal neo-vascularization in a mouse model of proliferative retinopathy. Because proliferative diabetic retinopathy is a recurrent disease, effective therapy will need to be sustained. Recombinant adeno-associated viruses permit long-term expression of transfected genes; however, they can only accommodate a small insert sequence. Thus, we engineered and tested a shortened recombinant angiostatin derivative containing a signal sequence to permit secretion. Recombinant protein was purified from the medium of transfected HEK293 cells and injected subcutaneously into treated animals. The retinal vasculature was analyzed in retinal flat mounts and using immunohistochemically stained sections. Both methods demonstrate that this short, secreted form of angiostatin is effective in reducing the development of blood vessels in a nontumor environment and has therapeutic potential for neovascular retinopathies such as diabetic retinopathy retinopathy of prematurity, retinal vein occlusion and, possibly, age-related macular degeneration.",
keywords = "Angiostatin, Neovascularization, Proliferative retinopathy",
author = "Meneses, {P. I.} and Hajjar, {K. A.} and Berns, {K. I.} and Robert Duvoisin",
year = "2001",
doi = "10.1038/sj.gt.3301423",
language = "English (US)",
volume = "8",
pages = "646--648",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Recombinant angiostatin prevents retinal neovascularization in a murine proliferative retinopathy model

AU - Meneses, P. I.

AU - Hajjar, K. A.

AU - Berns, K. I.

AU - Duvoisin, Robert

PY - 2001

Y1 - 2001

N2 - Retinal neovascularization is central to the pathogenesis of proliferative diabetic retinopathy, the leading cause of blindness among the middle-aged population. Angiostatin, a proteolytic fragment of plasminogen is one of the most promising inhibitors of angiogenesis currently in clinical trials. Here we show that recombinant angiostatin can inhibit retinal neo-vascularization in a mouse model of proliferative retinopathy. Because proliferative diabetic retinopathy is a recurrent disease, effective therapy will need to be sustained. Recombinant adeno-associated viruses permit long-term expression of transfected genes; however, they can only accommodate a small insert sequence. Thus, we engineered and tested a shortened recombinant angiostatin derivative containing a signal sequence to permit secretion. Recombinant protein was purified from the medium of transfected HEK293 cells and injected subcutaneously into treated animals. The retinal vasculature was analyzed in retinal flat mounts and using immunohistochemically stained sections. Both methods demonstrate that this short, secreted form of angiostatin is effective in reducing the development of blood vessels in a nontumor environment and has therapeutic potential for neovascular retinopathies such as diabetic retinopathy retinopathy of prematurity, retinal vein occlusion and, possibly, age-related macular degeneration.

AB - Retinal neovascularization is central to the pathogenesis of proliferative diabetic retinopathy, the leading cause of blindness among the middle-aged population. Angiostatin, a proteolytic fragment of plasminogen is one of the most promising inhibitors of angiogenesis currently in clinical trials. Here we show that recombinant angiostatin can inhibit retinal neo-vascularization in a mouse model of proliferative retinopathy. Because proliferative diabetic retinopathy is a recurrent disease, effective therapy will need to be sustained. Recombinant adeno-associated viruses permit long-term expression of transfected genes; however, they can only accommodate a small insert sequence. Thus, we engineered and tested a shortened recombinant angiostatin derivative containing a signal sequence to permit secretion. Recombinant protein was purified from the medium of transfected HEK293 cells and injected subcutaneously into treated animals. The retinal vasculature was analyzed in retinal flat mounts and using immunohistochemically stained sections. Both methods demonstrate that this short, secreted form of angiostatin is effective in reducing the development of blood vessels in a nontumor environment and has therapeutic potential for neovascular retinopathies such as diabetic retinopathy retinopathy of prematurity, retinal vein occlusion and, possibly, age-related macular degeneration.

KW - Angiostatin

KW - Neovascularization

KW - Proliferative retinopathy

UR - http://www.scopus.com/inward/record.url?scp=0035010785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035010785&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3301423

DO - 10.1038/sj.gt.3301423

M3 - Article

C2 - 11320411

AN - SCOPUS:0035010785

VL - 8

SP - 646

EP - 648

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 8

ER -